ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a 125 mcg every 2 weeks demonstrated sustained efficacy in RMS patients treated up to 5 years

Authors
Category Primary study
JournalNeurology
Year 2016
This article has no abstract
Epistemonikos ID: 0b0f5e97d34f37b9ee5b9a8ec6a5df44d8932132
First added on: Feb 07, 2025